Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q4 2019 · 10-K
Revenue$249.30M$249.30M+6.7% vs Q4 2018 Net Income$20.84M$20.84M+75.4% vs Q4 2018 EPS Diluted$0.40$0.40+81.8% vs Q4 2018 Gross Profit$111,210,000+6.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,638,000−64.2% Free Cash Flowderived$6,922,000−82.0% Margins · derivedGross margin44.6%−0.1 pt vs Q4 2018
Operating margin9.6%+3.5 pt vs Q4 2018
Net margin8.4%+3.3 pt vs Q4 2018
ended Mar 30, 2019 · filed May 22, 2019 · 53 d after period end